Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 4.9%. Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the electroCore Third Quarter 2024 ...

H.C. Wainwright raised the firm’s price target on electroCore (ECOR) to $22 from $15 and keeps a Buy rating on the shares after the firm ...

Electrocore (ECOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula ...

Core, Inc. (ECOR) shares soared 6% in the last trading session to close at $13.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus ...

An archived webcast of the event will be available on the “Investors” section of the company’s website at: www.electrocore.com. About electroCore, Inc. electroCore, Inc. is a commercial ...

Despite achieving its eighth consecutive record revenue quarter, electroCore Inc (ECOR) faces hurdles with net losses and ...

Greetings, and welcome to the electroCore Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce ...

ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness ...